JP2012530057A5 - - Google Patents

Info

Publication number

JP2012530057A5

JP2012530057A5 JP2012515147A JP2012515147A JP2012530057A5 JP 2012530057 A5 JP2012530057 A5 JP 2012530057A5 JP 2012515147 A JP2012515147 A JP 2012515147A JP 2012515147 A JP2012515147 A JP 2012515147A JP 2012530057 A5 JP2012530057 A5 JP 2012530057A5

Authority

JP

Japan

Prior art keywords

agent

drug

peptide

administered

medicament

Prior art date

2010-06-10

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000003814 drug Substances 0.000 claims 18
• 229940079593 drug Drugs 0.000 claims 12
• 108090000765 processed proteins & peptides Proteins 0.000 claims 9
• 239000003795 chemical substances by application Substances 0.000 claims 8
• 238000001356 surgical procedure Methods 0.000 claims 8
• 210000004556 brain Anatomy 0.000 claims 6
• 241000288906 Primates Species 0.000 claims 5
• 125000003275 alpha amino acid group Chemical group 0.000 claims 5
• 210000004204 blood vessel Anatomy 0.000 claims 5
• XWQVQFBTSBCKLI-FKXNDIMNSA-N dnc008987 Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 XWQVQFBTSBCKLI-FKXNDIMNSA-N 0.000 claims 5
• 206010002329 Aneurysm Diseases 0.000 claims 3
• 108700019745 Disks Large Homolog 4 Proteins 0.000 claims 3
• 102100022264 Disks large homolog 4 Human genes 0.000 claims 3
• 239000002260 anti-inflammatory agent Substances 0.000 claims 3
• 229940121363 anti-inflammatory agent Drugs 0.000 claims 3
• NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims 2
• 206010061216 Infarction Diseases 0.000 claims 2
• 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims 2
• 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims 2
• 230000000254 damaging effect Effects 0.000 claims 2
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
• 230000000694 effects Effects 0.000 claims 2
• 230000007574 infarction Effects 0.000 claims 2
• 208000037906 ischaemic injury Diseases 0.000 claims 2
• 238000000034 method Methods 0.000 claims 2
• 239000002831 pharmacologic agent Substances 0.000 claims 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 1
• 102100022397 Nitric oxide synthase, brain Human genes 0.000 claims 1
• 101710111444 Nitric oxide synthase, brain Proteins 0.000 claims 1
• 238000002583 angiography Methods 0.000 claims 1
• 208000013404 behavioral symptom Diseases 0.000 claims 1
• 239000008280 blood Substances 0.000 claims 1
• 210000004369 blood Anatomy 0.000 claims 1
• 230000002490 cerebral effect Effects 0.000 claims 1
• 238000011260 co-administration Methods 0.000 claims 1
• 238000002591 computed tomography Methods 0.000 claims 1
• 230000006378 damage Effects 0.000 claims 1
• 201000010099 disease Diseases 0.000 claims 1
• 208000035475 disorder Diseases 0.000 claims 1
• 210000003414 extremity Anatomy 0.000 claims 1
• 229960001340 histamine Drugs 0.000 claims 1
• 210000003630 histaminocyte Anatomy 0.000 claims 1
• 238000001802 infusion Methods 0.000 claims 1
• 239000003112 inhibitor Substances 0.000 claims 1
• 238000001990 intravenous administration Methods 0.000 claims 1
• 230000000302 ischemic effect Effects 0.000 claims 1
• 210000003734 kidney Anatomy 0.000 claims 1
• 238000002595 magnetic resonance imaging Methods 0.000 claims 1
• 239000002245 particle Substances 0.000 claims 1
• 210000001525 retina Anatomy 0.000 claims 1
• 210000000278 spinal cord Anatomy 0.000 claims 1